Orasure Technologies (OSUR)
NASDAQ:OSUR
Want to see OSUR full AI Analyst Report?
OSUR Stock Chart & Stats
$2.38
-$0.09(-2.38%)
At close: 4:00 PM EST
$2.38
-$0.09(-2.38%)
Day’s Range― - ―
52-Week Range$2.08 - $4.33
Previous CloseN/A
Volume226.53K
Average Volume (3M)771.42K
Market Cap
$275.39M
Enterprise Value$159.55M
Total Cash (Recent Filing)$176.96M
Total Debt (Recent Filing)$40.47M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Aug 11, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding68,848,560
10 Day Avg. Volume735,713
30 Day Avg. Volume771,421
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.52
Price to Sales (P/S)1.55
P/FCF Ratio-3.34K
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue1.41
Enterprise Value/Gross Profit3.44
Enterprise Value/Ebitda-2.51
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$119.68M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetOraSure's large cash buffer and minimal leverage give it durable financial flexibility to fund product launches, near-shoring and working capital while losses persist. A strong balance sheet reduces refinancing risk, supports buybacks and preserves optionality to invest or transact as revenue recovers.
Improving Gross MarginsSustained gross margin expansion from in‑sourcing, automation and manufacturing efficiencies indicates structural cost advantages in production. Higher gross margins provide a buffer against fixed operating costs and improve the path to profitability as volumes scale with new product adoption.
Product & Market CatalystsRegulatory submissions and early near‑shoring contracts are durable strategic moves: FDA clearances and partner commercialization can open recurring revenue streams, expand addressable markets (including public health programs) and diversify channels, supporting medium‑term structural growth if approvals and rollouts proceed.
Bears Say
Sharp Revenue DeclineA sustained ~26% revenue decline and the swing to deep net losses (~-62% net margin) reflect structural demand weakness or lost COVID-era volumes. This deterioration reduces operating leverage and makes return to durable profitability dependent on successful product ramps and market recovery.
Negative Cash GenerationPersistent negative operating and free cash flow means the core business is consuming cash rather than funding growth. Even with strong reserves, continued cash burn would force reliance on those reserves or external financing, constraining strategic flexibility and increasing execution pressure over the medium term.
Execution & Timing RiskKey growth drivers depend on FDA clearances, initial low volumes and partner rollouts that may be delayed or smaller than expected. Elevated near‑term opex and nonrecurring charges heighten the risk that margin benefits and cash breakeven targets slip, making recovery timing uncertain and execution‑dependent.
Orasure Technologies News
OSUR FAQ
What was Orasure Technologies’s price range in the past 12 months?
Orasure Technologies lowest stock price was $2.08 and its highest was $4.33 in the past 12 months.
What is Orasure Technologies’s market cap?
Orasure Technologies’s market cap is $275.39M.
When is Orasure Technologies’s upcoming earnings report date?
Orasure Technologies’s upcoming earnings report date is Aug 11, 2026 which is in 69 days.
How were Orasure Technologies’s earnings last quarter?
Orasure Technologies released its earnings results on May 06, 2026. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.23 by -$0.09.
Is Orasure Technologies overvalued?
According to Wall Street analysts Orasure Technologies’s price is currently Overvalued.
Does Orasure Technologies pay dividends?
Orasure Technologies does not currently pay dividends.
What is Orasure Technologies’s EPS estimate?
Orasure Technologies’s EPS estimate is -0.27.
How many shares outstanding does Orasure Technologies have?
Orasure Technologies has 68,848,560 shares outstanding.
What happened to Orasure Technologies’s price movement after its last earnings report?
Orasure Technologies reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.23. Following the earnings report the stock price went up 4.333%.
Which hedge fund is a major shareholder of Orasure Technologies?
Currently, no hedge funds are holding shares in OSUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orasure Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
OSUR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 159.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $224.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.53%
12-Months-Change
Fundamentals
Return on Equity
-21.50%
Trailing 12-Months
Asset Growth
-17.14%
Trailing 12-Months
Company Description
Orasure Technologies
OraSure Technologies, Inc. is a leader in the field of oral fluid diagnostics and medical devices, primarily focusing on the development and sale of products for the detection of infectious diseases and for drug testing. The company operates in two main sectors: the infectious disease testing market and the substance abuse testing market. Its core products include rapid diagnostic tests for HIV, HCV, and other infectious diseases, as well as oral fluid collection devices used for drug testing and other applications.
OSUR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: positive execution on cost and manufacturing initiatives led to gross margin expansion and sequential diagnostics growth, a strong cash position and ongoing buybacks support financial flexibility, and two FDA-submitted products plus near-shoring progress are meaningful near- to mid-term growth catalysts. Offsetting these positives are substantial operating losses, negative operating cash flow, elevated near-term operating expenses (including nonrecurring charges), muted demand in some Sample Management end markets due to slow NIH funding, and execution/timing risks associated with product ramps and near-shoring monetization. Given the mix of encouraging operational progress and clear near-term financial and execution risks, the overall tone is balanced.View all OSUR earnings summariesTechnical Analysis
InfuSystem Holdings
―
Stereotaxis
―
Utah Medical Products
―
Microbot Medical
―
Sanara MedTech
―
Ownership Overview
5.22% Insiders
16.97% Mutual Funds
31.00% Other Institutional Investors
34.59% Public Companies and
Individual Investors